| 03.30.22 | Chugai pays $25M to access subcutaneous tech; Court clears Purdue to fund opioid rescue spray

Laden...

2 jaren geleden

Html
Tekst

Webinar: Key Challenges & Opportunities in the Process Scale-Up of Oral Solid Dosage Forms

Tuesday, April 5 | 11am ET / 8am PT

Join this webinar to hear experts share insights into faster drug product manufacturing in a large-scale setting and discuss upcoming trends in oral solid dose form manufacturing. Register Now.

Today's Rundown

Roche's Chugai pays Halozyme $25M to access subcutaneous delivery tech Bankruptcy court clears Purdue to fund low-cost opioid rescue medication Vaxxas strikes deal to tee up trial of COVID-19 vaccine patch Seeking to shake up eye inflammation market, Optifye and DelSiTech partner on controlled-release drops AAD 2022: Incyte's latest Opzelura data show med's benefit grows over time in vitiligo

Featured Story

Roche's Chugai pays Halozyme $25M to access subcutaneous delivery tech

By Nick Paul Taylor

Chugai Pharmaceutical has struck a deal for a subcutaneous drug delivery technology, paying Halozyme Therapeutics $25 million upfront to use its Enhanze enzyme against an undisclosed target.

Webinar: Harnessing Quality Data and Digital Technology to Accelerate Patient-Centric Innovation

Wednesday, April 13, 2022 | 11am ET / 8am PT

During this webinar, we'll consider what digital transformation means for the future of pharmaceuticals, including a need to sustain this digital acceleration, the rise of virtual care and its effect on pharmaceuticals, and the need to implement Pharma 4.0 and Quality 4.0 concepts. Register Now.

Bankruptcy court clears Purdue to fund low-cost opioid rescue medication

By Nick Paul Taylor

A bankruptcy court has boosted Harm Reduction Therapeutics’ (HRT) bid to develop a low-cost opioid rescue medication. With the court handling Purdue Pharma’s case approving the transfer of cash to HRT, the nonprofit drug developer is set to receive up to $11 million.

Vaxxas strikes deal to tee up trial of COVID-19 vaccine patch

By Nick Paul Taylor

Vaxxas has secured an exclusive license to a SARS-CoV-2 spike protein from The University of Texas at Austin, positioning it to move a needle-free, room-temperature stable COVID-19 vaccine patch into the clinic.

Seeking to shake up eye inflammation market, Optifye and DelSiTech partner on controlled-release drops

By Nick Paul Taylor

Optifye Therapeutics has struck a deal with DelSiTech for controlled-release dexamethasone eye drops. The exclusive license agreement covers a candidate that uses DelSiTech Silica Matrix technology to cut the number of times a day patients need to administer the eye drops.

AAD 2022: Incyte's latest Opzelura data show med's benefit grows over time in vitiligo

By Fraiser Kansteiner

As Incyte Corporation awaits the FDA’s decision on a second dermatology nod for eczema newcomer Opzelura, the company is rolling out fresh 52-week data showing the benefits of its topical JAK inhibitor increase over time.

Webinar: Inside the Pharmacodynamic Toolbox: Developing CNS-Active Drugs Faster

Thursday, April 7, 2022 | 11:00 am ET / 8:00 am PT

Find out how to strategically include validated models of pain, anxiety, and other psychiatric conditions as part of a battery of tests for cognition and safety to evaluate a drug’s potential for abuse or dependence, as well as its ability to enhance or impair performance. Register now.

Resources

Industry Report: The Top Four Barriers to Successful KOL Engagement

eBook: Leveraging Clinical Data for Study Success

Sponsored by: Medidata, a Dassault Systèmes company

The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates.